Insulet (PODD) opened 2026 with Q1 revenue of US$761.7 million and basic EPS of US$1.30, while trailing twelve month revenue sat at about US$2.9 billion with basic EPS of US$4.31. This gives investors a clear view of both the quarterly print and the recent run rate. Over the last six reported quarters, revenue has moved from US$569 million in Q1 2025 to US$761.7 million in Q1 2026, with quarterly basic EPS ranging between US$0.32 and US$1.44 over that stretch. With trailing net profit margin at 10.4% versus 18.3% a year earlier, the latest numbers set up a debate around how much investors are willing to pay for current growth relative to softer recent profitability.

See our full analysis for Insulet.

With the headline results on the table, the next step is to line these figures up against the most common narratives around Insulet, highlighting where the numbers support the story and where they start to push against it.

Margins: 10.4% Today vs 18.3% A Year Ago

• Trailing net profit margin sits at 10.4% compared with 18.3% a year earlier, while trailing twelve month net income is US$302.8 million on US$2.9b of revenue.
• Bears highlight that this margin compression could limit how much operating leverage Insulet can get from Omnipod growth, yet
  • trailing twelve month Basic EPS of US$4.31 and five year annualized earnings growth of 52.2% show earnings have scaled meaningfully alongside revenue,
  • so the current margin level challenges the bearish view that higher spending automatically caps earnings power but does keep pressure on management to convert future revenue growth into stronger profitability.

Insulet's margin story is central to both bulls and bears, so it is worth seeing how earnings narratives line up against the latest numbers. 🐻 Insulet Bear Case

High Growth Expectations vs Recent EPS Pattern

• Q1 2026 Basic EPS of US$1.30 compares with US$1.44 in Q4 2025 and US$0.50 in Q1 2025, while trailing twelve month Basic EPS of US$4.31 sits against forecasts that earnings may grow about 22.3% per year.
• Supporters of the bullish narrative argue that expanding into a large underpenetrated type 2 diabetes market and global Omnipod rollouts can sustain high earnings growth, and
  • the move from US$569.0 million of revenue in Q1 2025 to US$761.7 million in Q1 2026 provides the revenue base that bulls point to,
  • but the dip from US$101.6 million of net income in Q4 2025 to US$91.1 million in Q1 2026 means the latest quarter has to work harder to back the idea of a smooth path toward higher profitability.

If you want to see how bullish investors connect these growth figures to a longer term story around Omnipod and new products, check out the 🐂 Insulet Bull Case

P/E Premium, DCF Gap and a 10.4% Margin

• With the stock at US$160.40, the trailing P/E of 36.7x sits above the US Medical Equipment industry average of 23.9x, while a DCF fair value of about US$326.22 and a 10.4% net margin create a wide gap between earnings quality, current pricing and that modelled value.
• Consensus style views often frame this as a trade off between strong growth signals and profitability pressure, because
  • revenue is forecast to grow around 15% per year with earnings growth near 22.3% per year, which lines up with the five year 52.2% annualized earnings growth history,
  • yet the margin move from 18.3% to 10.4% over the last year means investors are paying a premium P/E multiple for a business where recent profitability is lower than in the prior period even as the DCF fair value sits well above the current share price.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Insulet on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

All of this leaves a mix of optimism and caution. If you feel the clock is ticking on forming a clear view, start by weighing the 2 key rewards and 1 important warning sign.

See What Else Is Out There

Insulet pairs a premium 36.7x P/E with a lower 10.4% net margin and recent quarterly EPS softness, which raises questions about paying up for execution risk.

If that mix of rich pricing and pressure on profitability gives you pause, it is worth checking companies in the 50 high quality undervalued stocks that may offer stronger value on cleaner earnings profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.